Experimental immune cell therapy for leukemia shows promise but trial halted early
Disease control
Terminated
This study tested a special type of immune cell (MT-401) made from a donor's blood to treat acute myeloid leukemia (AML) after a stem cell transplant. The cells were designed to attack cancer cells while leaving healthy tissue alone. The trial aimed to see if this approach could …
Phase: PHASE2 • Sponsor: Marker Therapeutics, Inc. • Aim: Disease control
Last updated May 11, 2026 20:52 UTC